| Document |
Document Title |
|
JP3720400B2 |
PURPOSE: To obtain an immunorejection suppressing agent capable of suppressing immunorejection after organ transplantation, etc., and having little side effect by compounding amrinone as an active component. CONSTITUTION: This immunoreje...
|
|
JPWO2004009555A1 |
The following formula (1): which has myosin-controlled light chain phosphorylation inhibitory activity and is useful for the treatment of diseases related to contraction of various cells.[In the formula, R1Indicates a hydrogen atom, a ha...
|
|
JP2005534647A |
A polypeptide comprising the amino acid sequence: Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser...
|
|
JP2005312967A |
To provide a medicine and medicine distribution system which can be used for treating a vasal disease.A topical distribution system is covered by rapamycin or other suitable medicines, and a substance or a compound. It is distributed thr...
|
|
JP2005533054A |
Methods useful for preventing, limiting, or treating ischemia reperfusion injury in a mammal are disclosed. More particularly, this invention relates to administering A2b adenosine receptor antagonists to prevent, limit or treat ischemia...
|
|
JP2005530784A |
Methods of treating, preventing and/or managing cancer as well as diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory com...
|
|
JP2005530780A |
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokin...
|
|
JP2005529908A |
Ondansetron crystalline Forms A and B are useful in the treatment of nausea and vomiting. Form B has a uniquely high melting point of about 244° C. and both forms are stable against thermally induced polymorphic transition from 30° C. ...
|
|
JP2005529855A |
The present invention relates to a group of thiazole derivatives which are potent antagonists, agonists or partial agonists of the cannabinoid CB1-receptor. The compounds have the general formula (I) wherein R and R1-R4 have the meanings...
|
|
JP2005529622A |
The present invention relates to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococ...
|
|
JP2005529171A |
The use of corticotroph-derived glycoprotein hormone (CGH) to potentiate glucocorticoid action and to reduce glucocorticoid-induced adrenocortical suppression is described. CGH can be co-administered with glucocorticoids to enable a lowe...
|
|
JP2005529067A |
The use of chemokine receptor CCR5 modulators (e.g., CCR5 antagonists) is disclosed for the treatment or prevention of stress response (e.g., fever) in a subject resulting from surgery, infection or other insult to the subject (e.g., a w...
|
|
JP2005527518A |
Various chalcone derivatives of the general formula (I) are described and the variables, A, B, m and R1 to R10 are as defined in the specification. These derivatives can be useful in the modulation of potassium channel activity in cells ...
|
|
JP2005527197A |
Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifcally bind to the polypeptide, as well as derivatives, v...
|
|
JP2005526483A |
The invention provides purified preparations of prostaglandin E synthase (PGES), analogs and variants thereof, such as portions thereof, and fusion polypeptides comprising these. The invention also provides methods for obtaining these pu...
|
|
JP2005525848A |
The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide t...
|
|
JP2005525345A |
The present invention provides a novel method for treating and/or preventing thioredoxin (TRX)-mediated diseases and conditions, by administering to a subject in need of such treatment a therapeutically effective amount of a histone deac...
|
|
JP2005525327A |
The invention relates to N-substituted indole-3-acetic acid derivatives of the general formula in which R1 is optionally substituted benzothiazolyl, pyrimidin-4-yl, imidazol-2-yl, oxazol-2-yl or thiazol-2-yl, R2 is hydrogen, halogen, C1-...
|
|
JP2005523687A |
The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expre...
|
|
JP2005523248A |
Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibi...
|
|
JPWO2003083122A1 |
Provide means for treating and preventing vascular stenosis. The present invention comprises a vascular smooth muscle-specific expression replication viral vector that does not act on adult normal cells, characterized in that a transcrip...
|
|
JP3679710B2 |
A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulat...
|
|
JP2005521641A |
The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.
|
|
JP2005521670A |
Formulations containing a sodium hydrogen exchanger-1 (NHE-1) inhibitor for prevention of, inter alia, perioperative myocardial ischemic injury in mammals and a process for increasing the solubility of said inhibitor with methanesulfonic...
|
|
JP2005520819A |
A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C.
|
|
JP2005520811A |
Compounds according to formula (I) wherein n is 0-3, R<1> is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, R<8> and R<9> are ...
|
|
JP2005520801A |
Pyrrolopyrimidine derivatives of the formula I in which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rh...
|
|
JP2005519917A |
Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent...
|
|
JP2005519885A |
The present invention relates to novel compounds and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and...
|
|
JP2005519881A |
The present invention relates to methods for inhibiting or preventing ocular processes associated with CTGF. Methods and agents for use in treating or preventing ocular disorders, methods for diagnosing ocular disorders and related kits,...
|
|
JP2005519080A |
The invention relates to the local administration of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylp
henyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt or crystal form thereof, optionally in conjun...
|
|
JP2005154305A |
To provide a method for producing a hyaluronic acid-containing composition having high viscosity and only specifically improved elasticity in viscoelasticities.This method for producing the hyaluronic acid-containing composition comprise...
|
|
JP2005515976A |
Compounds of the formula (I), useful as metal-loproteinase inhibitors, especially as inhibitors of MMP12
|
|
JP2005139203A |
To provide IGF-I and insulin variants selectively bonding to IGFBP-1 (IGF bonding protein-1) and IGFBP-3.The IGF-I variant comprises natural sequence human IGF-1 whose amino acid are substituted at a position of 3, 4, 5, 6, 7, 10, 14, 17...
|
|
JPWO2003067979A1 |
The present invention relates to a preservative for a heart for transplantation and an agent for suppressing ischemia-reperfusion injury after heart transplantation, which contains a pyrazolone derivative of the following formula (I) as ...
|
|
JP2005514960A |
Methods and materials for treating tissues to reduce the risk of transplant rejection are described, along with methods for determining the risk of rejection of transplants. The level of expression of various senescence-associated genes,...
|
|
JP2005132831A |
To prepare a transfusion for intravenous administration, capable of being administered safer than ever, by preventing onset of phlebitis which frequently occurs in conventional transfusions for peripheral intravenous administration, capa...
|
|
JP2005514375A |
This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) acti...
|
|
JP2005510514A |
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and PAI-1 or a PAI-1-related polypeptide, and the use thereof for treating bleeding episodes.
|
|
JP2005510515A |
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein C inhibitor, and the use thereof for treating bleeding episodes.
|
|
JP3640655B2 |
To obtain a neovascularization-inducing agent comprising fibrin which is safe for living bodies, has good adhesiveness to the living bodies, and is administered into organs or tissues for neovascularization. This neovascularization-induc...
|
|
JP2005097313A |
To provide a medicine for treating human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe bur...
|
|
JPWO2003047624A1 |
Vascular diseases and kidneys with migration of vascular smooth muscle cells and mesangial cells, which contain a growth hormone secretagogue receptor agonist having an excellent inhibitory effect on the migration of vascular smooth musc...
|
|
JP2005508336A |
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
|
|
JP2005508360A |
The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.
|
|
JP2005508348A |
Orally disintegrating valdecoxib fast-melt tablets and processes for preparing such dosage forms are provided. The compositions are useful in treatment or prophylaxis of cycloosygenase-2 mediated conditions and disorders.
|
|
JP2005507866A |
Polymeric compositions containing a high percentage of bound polypropylene glycol provide matrices for the controlled release of drugs and medicinal agents. The compositions are prepared by the polymerization of ethylenically unsaturated...
|
|
JP2005507647A |
The present invention relates to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides der...
|
|
JPWO2003043663A1 |
Providing new and effective strategies for organ transplantation. Provided are therapeutic agents and methods for preventing acute rejection of transplanted organs and improving prognosis. A therapeutic agent that suppresses rejection in...
|
|
JPWO2003037862A1 |
In the present invention, the following formula [1] (n represents 0 or 1. X represents CR4 or N, Y represents CR6 or N, Z represents CR7 or N. R1, R2 are the same or Differently, they represent hydrogen, optionally substituted alkyls, ac...
|
